ライフサイエンスコーパス: maribavir

1 -2-isopropylamino-5,6-dichlorobenzimidazole (maribavir).

2 duction and nuclear egress in the absence of maribavir.

3 ausea, and vomiting, were more frequent with maribavir.

4 ect can be antagonized by the antiviral drug maribavir.

5 cells treated with the UL97 kinase inhibitor maribavir.

6 ding frames that could explain resistance to maribavir.

7 ro) as the one responsible for resistance to maribavir.

8 s or with wild-type virus in the presence of maribavir.

9 ectly involved in the mechanism of action of maribavir.

10 al kinase was shown to be a direct target of maribavir.

11 pe virus and was resistant to both BDCRB and maribavir.

12 in II and inhibited by a new antiviral drug, maribavir.

13 cifically inhibited by a new antiviral drug, maribavir.

14 the efficacy and safety of prophylactic oral maribavir (100 mg twice daily) for prevention of CMV dis

15 e randomized to receive CMV prophylaxis with maribavir (100 mg twice daily, 400 mg once daily, or 400

16 tant resistant to the benzimidazole compound maribavir (1263W94), reflecting the anti-UL97 effect of

17 n patients receiving each respective dose of maribavir (15%, P = .001; 30%, P = .051; 15%, P = .002)

18 recipients with CMV-seropositive donors (147 maribavir; 156 ganciclovir).

19 Understanding UL97 function and maribavir action should help elucidate this interesting

20 We used maribavir and a UL97 null mutant, which is severely defi

21 val, and non-CMV infections were similar for maribavir and ganciclovir patients.

22 residues and was sensitive to inhibition by maribavir and to a mutation that inactivates UL97 cataly

23 was passaged in increasing concentrations of maribavir, and resistant virus was isolated.

24 Novel therapies such as maribavir, brincidofovir, and letermovir should be furth

25 These results show that maribavir can reduce the incidence of CMV infection and,

26 ent-to-treat analysis, the noninferiority of maribavir compared to oral ganciclovir for prevention of

27 igenemia was lower in each of the respective maribavir groups (15%, P = .046; 19%, P = .116; 15%, P =

28 CMV DNA was lower in each of the respective maribavir groups (7%, P = .001; 11%, P = .007; 19%, P =

29 Maribavir had no adverse effect on neutrophil or platele

30 The ineffectiveness of the UL97 inhibitor maribavir in clinical trials might be better explained w

31 egalovirus (CMV) activity and safety of oral maribavir in CMV-seropositive allogeneic stem-cell trans

32 pylamino-5,6-dichlorobenzimidazole (1263W94; maribavir), inhibits viral DNA synthesis and nuclear egr

33 Maribavir is an oral benzimidazole riboside with potent

34 At a dose of 100 mg twice daily, maribavir is safe but not adequate for prevention of CMV

35 Maribavir (MBV) inhibits Epstein-Barr virus (EBV) replic

36 cytomegalovirus (CMV) UL97 kinase inhibitor maribavir (MBV) is undergoing clinical antiviral trials.

37 More recently, maribavir (MBV), an l-ribofuranoside benzimidazole, has

38 compounds with new molecular targets such as maribavir (MBV), FV-100, AIC361, and AIC246.

39 When T2294 was serially passed under maribavir (MBV), phenotypic changes and viral UL97 mutat

40 viral activity of the pUL97 kinase inhibitor maribavir (MBV).

41 Testing the recombinants for sensitivity to maribavir narrowed the locus of resistance to genes UL26

42 kinase activity using the antiviral compound maribavir or deletion of the UL97 gene resulted in decre

43 nt of infected cells with the UL97 inhibitor maribavir or infection with a UL97 mutant led to a punct

44 Inhibition of UL97 kinase activity with maribavir or mutation of an essential amino acid in the

45 pp65 antigenemia or CMV DNA PCR compared to maribavir patients at both 100 days (20% vs. 60%; p < 0.

46 disease in placebo patients but none in the maribavir patients.

47 ral shedding was cleared without evidence of maribavir resistance in an isolate obtained after therap

48 ion and showed slight growth attenuation and maribavir resistance in cell culture.

49 The relatively rapid onset of maribavir resistance probably resulted from incomplete v

50 UL97 mutations T409M and H411Y, which confer maribavir resistance.

51 ents confirmed that UL27 mutations conferred maribavir resistance.

52 ese strains showed lower-grade resistance to maribavir than the UL97 mutant.

53 e-resistant structures in mutant-infected or maribavir-treated cells under conditions where the virus

54 rare in the cytoplasm of mutant-infected or maribavir-treated cells; the magnitudes of these decreas

55 of CMV disease was not established (12% with maribavir vs. 8% with ganciclovir: event rate difference

56 Resistance to maribavir was mapped to UL97, and this viral kinase was

57 mental cytomegalovirus UL97 kinase inhibitor maribavir was used to treat 2 cases of infection in whic

58 Maribavir was well-tolerated and associated with fewer h

59 on Ser-38 and was specifically sensitive to maribavir, whereas phosphorylation of this peptide by cA